Quote: "I believe that with the use of cavitation technology to harvest the stromal vascular fraction from a lipoaspirate without chemicals and enzymes, we would be able to capture the appropriate stem cells with their micromatrix and microenvironment for use in patients with failing hearts and lungs."
In his research role at the UA, he is the director of the Ex Vivo Lung Program, clinical and translational research, and the Cardiopulmonary Stem Cell Bank. Dr. Khalpey also holds a position on the UA Institutional Review Board (IRB).
He also is involved in creating clinical “bridge-to-regeneration” trials, in which autologous stem cells will be injected into failing hearts with the hope of recovery in an era of limited hearts for transplantation.
International patent checklist: 1. Amendments completed----CHECK! 2. Publication of bibliographic data---CHECK! 3. Request for examination-----CHECK! 4. Translation done-----CHECK! 5. All fees paid----CHECK! 6. Entry into Regional Phase---CHECK! 7. International preliminary written opinion YES for all 3 core components; Novelty, Inventive Step and Industrial Applicability!----CHECK!
SVFC awaiting grant of International Patent by EPO...everything has been completed:)
SVFC US Patented Stem Cell Technology validated by Millipore!
Millipore studies: [0013] Figures 1A-E, 2A-E, 3A-E, 4A-E and 5A-E contain the results of Milipore studies that compare the stromal vascular fraction cells isolated according to the inventive ultrasonication methods vis-a-vis methods that use collagenase. The results therein show that the subject ultrasonication protocol results in about 10-fo!d more viable cells than comparable adipose samples (same amount of adipose tissue) which were treated with an enzyme that breaks down collagen (collagenase). The results therein further show that the inventive methods result in the same cell population and cell types as collagenase isolation procedures, suggesting that the inventive methods preserve the integrity of all the desired stromal vascular fraction cells, and especially the cell types identified in the Figures.
Quote:" However, if autologous stem cells are harvested, processed, and implanted without the concerning enzymatic process, and if the entire procedure is done in only a short time at the bedside point of care, it will cost far less than existing methods and can save the patient and the physician a great deal of time."
Quote:"There is also the yet established safety of the enzymes used to separate the stem cells from fat being potentially harmful to the patient."
****SVFC Technology Stem Cell Technology does not require enzymes, is cost effective, clinically safe, and produces 10X count and greater number of cells.
SVFC will be the leader in the area of Stem Cell Regenerative Medicine!
Answer to who will win the stem cell race?.....SVFC...of corse!
SVFC $$$$...massive upside potential for this undervalued emerging stem cell biotech with US Patented Stem Cell tech granted, five European Patents in National Phase, International patent in final stage of grant with provisional patent protection effective 11/06/13, and positive International Preliminary Written Opinion by the Patent Cooperation Treaty a YES for ALL 3 core requirements; Novelty, Inventive Step, and Industrial Applicability! More monster news to be announced at any time...2014 will be epic!